{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:03:54Z","timestamp":1780455834704,"version":"3.54.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","award":["NRPU-8801"],"award-info":[{"award-number":["NRPU-8801"]}],"id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0231480","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:27:18Z","timestamp":1586539638000},"page":"e0231480","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment na\u00efve HCV positive Pakistani patients"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-7644","authenticated-orcid":true,"given":"Hafeez Ullah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-3036","authenticated-orcid":true,"given":"Sanaullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-0575","authenticated-orcid":true,"given":"Muhammad Akbar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-535X","authenticated-orcid":true,"given":"Sobia","family":"Attaullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6381-1746","authenticated-orcid":true,"given":"Muhammad Arshad","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"issue":"3","key":"pone.0231480.ref001","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2221-1691(15)30004-6","article-title":"Viral hepatitis in Pakistan: challenges and priorities","volume":"5","author":"S Ashraf","year":"2015","journal-title":"Asian Pac J Trop Biomed"},{"key":"pone.0231480.ref002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir","volume":"151","author":"C Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0231480.ref003","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response","volume":"151","author":"NA Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0231480.ref004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"151","author":"JM Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0231480.ref005","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"2s5","author":"DL Wyles","year":"2017","journal-title":"Topics Antiviral Med"},{"issue":"7","key":"pone.0231480.ref006","doi-asserted-by":"crossref","first-page":"e02601","DOI":"10.1128\/AAC.02601-17","article-title":"Unexpected replication boost by simeprevir for simeprevir-resistant variants in genotype 1a hepatitis C virus","volume":"62","author":"K Murai","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0231480.ref007","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"DJ Bartels","year":"2013","journal-title":"J Virol"},{"key":"pone.0231480.ref008","first-page":"1","article-title":"Clinical implications of detectable baseline hepatitis C virus-genotype 1NS3\/4Aprotease variants on the efficacy of boceprevir combined with peginterferon\/ribavirin","volume":"1","author":"JA Howe","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"pone.0231480.ref009","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"O Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0231480.ref010","first-page":"1","article-title":"Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients","author":"Z Li","year":"2017","journal-title":"BioMed Res Int"},{"issue":"6","key":"pone.0231480.ref011","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1089\/mdr.2018.0360","article-title":"Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection","volume":"25","author":"W Huang","year":"2019","journal-title":"Microb Drug Resist"},{"issue":"7","key":"pone.0231480.ref012","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3851\/IMP1900","article-title":"NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1\u20135","volume":"16","author":"S Vallet","year":"2011","journal-title":"Antivir Ther"},{"issue":"5","key":"pone.0231480.ref013","doi-asserted-by":"crossref","first-page":"e1004128","DOI":"10.1371\/journal.ppat.1004128","article-title":"Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents","volume":"10","author":"F Xiao","year":"2014","journal-title":"PLoS Pathog"},{"key":"pone.0231480.ref014","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12985-015-0414-1","article-title":"Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-na\u00efve patients with chronic hepatitis C","volume":"12","author":"A Costantino","year":"2015","journal-title":"Virol J"},{"issue":"1","key":"pone.0231480.ref015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.35.1.201-207.1997","article-title":"New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a","volume":"35","author":"O Ohno","year":"1997","journal-title":"J Clin Micobiol"},{"issue":"9","key":"pone.0231480.ref016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-na\u00efve patients","volume":"24","author":"S Paolucci","year":"2012","journal-title":"Virol J"},{"issue":"6","key":"pone.0231480.ref017","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle","volume":"60","author":"SBN Serre","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0231480.ref018","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12985-017-0829-y","article-title":"Prevalence of hepatitis-C virus genotyes and potential transmission risks in Malakand Khyber Pakhtunkhwa Pakistan","volume":"14","author":"N Nazir","year":"2017","journal-title":"Virol J"},{"issue":"4","key":"pone.0231480.ref019","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3748\/wjg.v22.i4.1684","article-title":"Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data","volume":"22","author":"M Umer","year":"2016","journal-title":"World J Gastroenterol"},{"key":"pone.0231480.ref020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"T Shimakami","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"pone.0231480.ref021","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"DJ Bartels","year":"2013","journal-title":"J Virol"},{"key":"pone.0231480.ref022","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/gutjnl-2012-304370","article-title":"Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality","volume":"63","author":"CJ Liu","year":"2014","journal-title":"Gut"},{"key":"pone.0231480.ref023","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.01976-13","article-title":"Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir","volume":"58","author":"K.L Berger","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0231480.ref024","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jhep.2018.10.031","article-title":"HCV genotype 1\u20136 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape","volume":"70","author":"LV Pham","year":"2019","journal-title":"J Hepatology"},{"key":"pone.0231480.ref025","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S2210-7401(11)70005-5","article-title":"Mechanisms of non-response to antiviral treatment in chronic hepatitis C","volume":"35","author":"S Chevaliez","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"pone.0231480.ref026","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/JCM.00838-12","article-title":"Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy","volume":"50","author":"ES Svarovskaia","year":"2012","journal-title":"J Clin Microbiol"},{"key":"pone.0231480.ref027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virusres.2013.08.001","article-title":"Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV\/HCV coinfected patients","volume":"177","author":"B Bartolini","year":"2013","journal-title":"Virus Research"},{"key":"pone.0231480.ref028","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2147\/PPA.S172732","article-title":"Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir\/grazoprevir","volume":"12","author":"X Ng","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"pone.0231480.ref029","doi-asserted-by":"crossref","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","article-title":"Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients","volume":"10","author":"J Dietz","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"pone.0231480.ref030","doi-asserted-by":"crossref","first-page":"e00363","DOI":"10.1128\/AAC.00363-17","article-title":"Antiviral Activity and Resistance Analysis of NS3\/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons","volume":"61","author":"E Asante-Appiah","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0231480.ref031","unstructured":"European Association for the Study of the Liver (EALS). 2018. Recommendations of treatment of HCV. http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/easl-recommendations-on-treatment-of-hepatitis-c-2018. Accessed on 10 August 2018."},{"issue":"5","key":"pone.0231480.ref032","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1473-3099(13)70074-4","article-title":"Sofosbuvir: the final nail in the coffin for hepatitis C?","volume":"13","author":"MP Manns","year":"2013","journal-title":"The Lancet Inf Dis"},{"key":"pone.0231480.ref033","doi-asserted-by":"crossref","first-page":"R16","DOI":"10.1186\/gb-2008-9-1-r16","article-title":"Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus","volume":"9","author":"C Welsch","journal-title":"Genome Biol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:27:43Z","timestamp":1586539663000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0231480"}},"subtitle":[],"editor":[{"given":"Jason","family":"Blackard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0231480","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]}}}